Histogenics (NASDAQ:HSGX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05), MarketWatch Earnings reports.
NASDAQ:HSGX traded down $0.03 during mid-day trading on Friday, hitting $0.51. The stock had a trading volume of 1,795,036 shares, compared to its average volume of 8,070,151. Histogenics has a twelve month low of $0.50 and a twelve month high of $3.35. The company has a market capitalization of $15.64 million, a P/E ratio of -0.52 and a beta of 1.02.
Several equities research analysts recently issued reports on HSGX shares. HC Wainwright set a $1.00 target price on shares of Histogenics and gave the company a “buy” rating in a research note on Friday. Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a research note on Wednesday, August 1st. Zacks Investment Research downgraded shares of Histogenics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Needham & Company LLC raised their target price on shares of Histogenics to $5.00 and gave the company a “buy” rating in a research note on Thursday, September 6th. Finally, BTIG Research downgraded shares of Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 target price for the company. in a research note on Wednesday, September 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $3.25.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Week Herald and is owned by of Week Herald. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://weekherald.com/2018/11/10/histogenics-hsgx-releases-earnings-results-misses-estimates-by-0-05-eps.html.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Read More: NASDAQ Stock Market Explained
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.